Saturday 17 October 2026 Export CRVO’s income statement to Excel — free account

CervoMed Inc.

CervoMed Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.0 million, down 58.9% from fiscal 2024. In the quarter to June 2026, revenue fell 99.6%, EPS grew 8.57% and free cash flow fell 6.20%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

2.24 0.01 −0.44%

Follow CRVO

Alert me

Market cap: $34.0M
P/E: 0.0×
Fwd P/E: −1.1×
Dividend yield: —
F-score: 2/9
Altman Z: 0.28
Beneish M: −4.94
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 3.74

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	10	—	—	—	—	—	—	1	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 5.32%

Capital & Financial Ratios $m

Market Cap 34.02

Revenue 4.01

Net Income (30.35)

Free Cash Flow (27.98)

Net Debt (24.94)

Current Ratio 8.57

Debt/Equity 0.00

P/E ratio 0.00

Fwd P/E (1.09)

P/S ratio 5.73

P/B ratio 1.00

Past 5Y EPS Growth —

This Y EPS Growth 27.74%

Next Y EPS Growth 31.18%

Next Y revenue growth (96.67%)

Next 5Y EPS Growth 28.27%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 28.76%

10-year low 10-year high

P/B against its own 10 years 40.33%

10-year low 10-year high

EV/Sales against its own 10 years 8.87%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2017	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	8	39	21	25
Receivables	1	2	0	—
Inventory	—	—	—	—
Other	—	—	—	—
	10	43	23	26

	2023	2024	2025	Q'26
Payables	1	2	1	1
ST’ Debt	—	—	—	—
Other	—	—	—	—
	3	4	5	3

Compound Annual Growth %

	10y	5y	3y
Sales	—	—	—
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	0.00%	(5.99%)	0.00%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	—	—	—	—	—
’25	2	2	0	0	4
’24	2	3	2	2	10

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(8)	(7)	—	—	—
’25	(4)	(7)	(6)	(7)	(23)
’24	(1)	(2)	(5)	(8)	(17)
’23	(1)	(2)	(1)	(3)	(7)
’22	(5)	(4)	7	(1)	(3)
’21	(5)	(3)	(3)	(3)	(15)
’20	(4)	(3)	(4)	(3)	(14)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(8)	(7)	—	—	—
’25	(4)	(7)	(6)	(7)	(23)
’24	(1)	(2)	(5)	(8)	(17)
’23	(1)	(2)	(1)	(3)	(7)
’22	(5)	(4)	7	(1)	(3)
’21	(5)	(3)	(3)	(3)	(14)
’20	(4)	(3)	(4)	(3)	(14)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.86)	(0.64)	—	—	—
’25	(0.56)	(0.70)	(0.84)	(0.88)	(2.98)
’24	(0.41)	(0.27)	(0.55)	(0.80)	(2.02)
’23	(1.03)	(2.75)	0.57	2.40	(0.82)
’22	(3.33)	(3.09)	(2.05)	(3.09)	(11.20)
’21	(4.50)	(3.00)	(9.00)	(3.00)	(18.75)
’20	(5.25)	(7.50)	(5.25)	(4.50)	(22.50)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	900.00	1,192.50	137.25	15.75	18.75	21.75	6.96	4.14	1.80	1.92	Analyst estimates 2026–2028 Powerpack
	High	19,125.00	17,437.50	2,340.00	825.00	120.00	138.75	30.00	14.37	26.38	16.94
People
People	Employees	10	11	10	10	13	16	13	8	15	15
	Revenue/emp, $m	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.89	0.65	0.27
Income, $m
Income, $m	Revenue	—	—	—	—	—	—	—	7	10	4
	Gross margin, %	0.00	0.00	0.00	0.00	0.00	0.00	—	100.00	100.00	100.00
	EBT	(18)	(2)	(19)	(11)	(16)	(25)	(6)	(2)	(16)	(27)
	EBT margin, %	0.00	0.00	0.00	0.00	0.00	0.00	0.00	(30.40)	(167.29)	(673.07)
	Net income	(18)	(1)	(18)	(12)	(14)	(24)	(6)	(2)	(16)	(27)
	Depreciation	0	0	7	0	0	0	—	—	—	—
Per share, $
Per share, $	Revenue	0.00	0.00	0.00	0.00	0.00	0.00	0.00	2.69	1.21	0.44
	Earnings	(1,978.91)	(236.12)	(615.72)	(131.99)	(22.50)	(18.75)	(11.47)	(0.82)	(2.02)	(2.98)
	Cash flow	(1,183.33)	(1,121.13)	(249.37)	(110.27)	(18.88)	(11.17)	(4.97)	(2.80)	(2.05)	(2.59)
	Capex	(0.25)	(40.71)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	Free cash flow	(1,183.58)	(1,161.84)	(249.37)	(110.27)	(18.88)	(11.17)	(4.97)	(2.80)	(2.05)	(2.59)
	Book value	1,009.31	1,929.99	361.38	225.22	34.57	26.89	(17.37)	2.77	4.86	2.02
	Shares, m	0	0	0	0	1	1	1	3	8	9
Valuation, ×
Valuation, ×	P/E	—	—	—	—	—	—	—	0.00	0.00	0.00
	P/S	—	—	—	—	—	—	—	2.98	1.94	17.83
	P/B	—	—	—	—	—	—	—	2.89	0.48	3.92
	EV/Sales	—	—	—	—	—	—	—	3.70	(0.73)	15.86
	EV/FCF	—	—	—	—	—	—	—	(3.35)	0.42	(2.66)
Cash, $m
Cash, $m	Operating cash flow	(11)	(12)	(11)	(10)	(14)	(15)	(3)	(7)	(17)	(23)
	Capex	0	0	—	—	—	0	—	—	—	—
	Free cash flow	(11)	(13)	(11)	(10)	(14)	(14)	(3)	(7)	(17)	(23)
Balance, $m
Balance, $m	Working capital	(3)	7	8	13	16	35	3	7	39	18
	Total debt	2	1	—	0	0	—	12	—	—	—
	Net debt	1	(8)	(8)	(14)	(18)	(37)	8	(8)	(39)	(21)
	Shareholders’ equity	9	21	16	20	25	35	(9)	7	39	18
Returns, %
Returns, %	ROA	(182.55)	(12.00)	(120.07)	(55.77)	(62.25)	(73.50)	(27.64)	(30.74)	(61.41)	(81.77)
	ROIC	(114.12)	(55.05)	(155.49)	(118.50)	(157.62)	0.00	0.00	0.00	(4,064.19)	0.00
	ROE	(394.54)	(17.21)	(144.53)	(66.02)	(71.80)	(80.69)	(713.60)	16.77	(69.95)	(93.92)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Dec 2025

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
EDSA Edesa Biotech, Inc.	$36.1M	— (loss-making)	— (loss-making)	−99.88% (below 0%: shrinking)	n/m	−81.24% (below 0%: shrinking)	0.00%	0.00%	Compare
NNVC NanoViricides, Inc.	$35.0M	— (loss-making)	—	—	n/m	−23.94% (below 0%: shrinking)	0.00%	0.00%	Compare
LIANY LianBio Sponsored ADR	$34.2M	0.0×	—	—	n/m	+1,107.59% (above 0%: growing)	0.00%	0.00%	Compare
CRVO CervoMed Inc.	$34.0M	— (loss-making)	— (loss-making)	−99.60% (below 0%: shrinking)	n/m	−6.20% (below 0%: shrinking)	100.00%	0.00%
IRLA Quince Therapeutics, Inc.	$33.8M	— (loss-making)	—	—	n/m	−63.65% (below 0%: shrinking)	0.00%	0.00%	Compare
ALGS Aligos Therapeutics, Inc.	$33.7M	— (loss-making)	— (loss-making)	+2,778.55% (above 0%: growing)	n/m	−59.81% (below 0%: shrinking)	100.00%	(6.80%)	Compare
ATNM Actinium Pharmaceuticals, Inc.	$33.3M	3.1×	— (loss-making)	+77,677.78% (above 0%: growing)	n/m	−4.91% (below 0%: shrinking)	100.00%	78.76%	Compare
BCTX BRIACELL THERAP	$32.8M	1.5×	—	—	n/m	+0.21% (above 0%: growing)	0.00%	0.00%	Compare
GNTA Genenta Science S.p.A. Unsponsored ADR	$32.3M	—	—	—	—	+35.94% (above 0%: growing)	0.00%	—	Compare
Median of peers	$33.7M	1.5×	—	+2,778.55%	—	−14.42%	0.00%	0.00%

All 614 Biotechnology stocks →

CervoMed Inc. (CRVO) key facts

Concern: CervoMed Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.0 million, down 58.9% from fiscal 2024.
CervoMed Inc. (CRVO) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, CRVO traded at $2.24, a market capitalization of $34.0 million.
Return on equity was −93.9% and debt-to-equity 0.00.
Its Piotroski F-score is 2 out of 9 and its Altman Z-score is 0.28 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.